All patients | IRF-1 High | IRF-1 Low | ||
---|---|---|---|---|
N | 47 | 31 | 16 | |
Median age at diagnosis | 62 | 63 | 60 | |
Sex | Male | 24 | 14 | 10 |
Female | 23 | 17 | 6 | |
Race | White | 44 | 30 | 14 |
Black | 2 | 0 | 2 | |
Hispanic | 1 | 1 | 0 | |
Treatment | Pembrolizumab | 18 | 12 | 6 |
Nivolumab | 10 | 4 | 6 | |
Ipilimumab + nivolumab | 19 | 15 | 4 | |
Prior checkpoint blockade | Yes | 16 | 11 | 5 |
No | 31 | 20 | 11 | |
Mutation status | BRAF | 16 | 11 | 5 |
NRAS | 6 | 5 | 1 | |
CKIT | 2 | 2 | 0 | |
None detected | 23 | 13 | 10 | |
Stage at diagnosis | I | 5 | 3 | 2 |
II | 8 | 5 | 3 | |
III | 17 | 11 | 6 | |
IV | 11 | 8 | 3 | |
Unknown | 6 | 4 | 2 |